The article highlights the potentially game-changing approach of the Company towards treating Alzheimer’s Disease, based on technology developed at Rutgers by Dr. Luciano D’Adamio, PhD, MD, New Jersey ...

today announced that it has achieved a key safety data milestone supporting expanded and longer-term clinical studies of its novel TNF-alpha (TNF-α) inhibitor drug, isomyosamine, in multiple ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an osteoarthritis treatment in human trials may have potential for treating RA.

Understanding these risks is the first step toward creating a cleaner, safer future. Researchers make alarming new discovery while investigating side effects of cigarettes — here's what they found ...

We spoke with registered dietitians to break down the benefits, potential risks and what you should know before adding ...

Bio-Thera will obtain an upfront payment of $21m and could earn up to $143.5m in development and commercial milestones.

A doctor may prescribe injectable treatments, such as methotrexate, TNF-alpha inhibitors, or interleukin inhibitors, for moderate to severe psoriasis when other treatments don’t work.

The addition of tumor-necrosis factor-α (TNF-α) to this treatment approach has changed the situation dramatically. High response rates and limb-salvage rates have been reported in multicenter ...

though the use of tumor necrosis factor-alpha inhibitors may offer protective benefits. Children with rheumatic diseases face heightened risks for severe COVID-19 outcomes, with certain medications ...